Gabapentin Tablet
Product Images NDC 58118-2126

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58118-2126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

An illustration showing the formula for calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Figure1 (Figure1)

Line graph showing the mean pain score over an 8-week period, comparing placebo and gabapentin at a 3600 mg/day dosage. The graph is divided into a 4-week dose titration period and a 4-week fixed-dose period, with pain scores decreasing more notably for gabapentin compared to placebo over time.*

FDA Label Image

Figure2 (Figure2)

A line graph displaying mean pain scores over seven weeks comparing placebo and gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis shows weeks from baseline to week 7, and the y-axis represents mean pain scores ranging from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure3 (Figure3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) dosages in two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers indicate p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (Figure4)

A scatter plot graph depicting the percentage difference versus daily dose in mg for Gabapentin. The x-axis shows daily doses of 600, 900, 1200, and 1800 mg, while the y-axis shows the difference percentage ranging from 2% to 22%. Data points from three studies labeled a, b, and c are shown with distinct shapes and colors, illustrating how the difference percentage varies with dose across the studies.*

FDA Label Image

Glenmarklogo1 (Glenmarklogo1)

FDA Label Image

Glenmarklogo2 (Glenmarklogo2)

FDA Label Image

Gabapentin 600mg Tablets 30ct Blister Card (Label600mg)

Label for Gabapentin 600 mg tablets by Clinical Solutions Wholesale. The label includes NDC 58118-2126-8, quantity of 30 tablets, manufacturing details by Glenmark Pharmaceuticals in Mahwah, NJ, and storage instructions. Includes GTIN, batch number, and expiration year 2027.*

FDA Label Image

Gabapentin 800mg Tablets 30ct Blister Card (Label800mg)

Gabapentin 800 mg tablets label from Clinical Solutions Wholesale showing a package quantity of 30 tablets. The label includes NDC 58118-2127-8, manufacturer Glenmark Pharmaceuticals, and batch/sample information with an expiration date of September 2027. The tablets are for oral use.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of gabapentin showing the cyclohexane ring attached to an amino group and a carboxylic acid group, representing the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.